Harmony Biosciences Reports First Quarter 2021 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Harmony Biosciences (HRMY) Tops Q1 EPS by 16c, Revenues Beat
May 11, 2021 8:04 AM EDTHarmony Biosciences (NASDAQ: HRMY) reported Q1 EPS of $0.13, $0.16 better than the analyst estimate of ($0.03). Revenue for the quarter came in at $59.7 million versus the consensus estimate of $57.07 million.
First Quarter 2021 Highlights:
Net product revenue of $59.7 million for the quarter ended March 31, 2021;Significant growth in WAKIX sales, supported by the addition of the cataplexy indication, which strengthens the overall... More